Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests
Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b clinical trial. “This is exciting data that validates our confidence in the future of the [Veyonda-radiotherapy] treatment regimen,” Graham Kelly, PhD, Noxopharm’s executive chairman and CEO, said in a press release. Based on these positive results, Noxopharm plans to launch a Phase 2/3 study to evaluate the combination therapy later this year, which the company "hopes will be the final step to obtaining marketing approval." Formerly known as NOX66, Veyonda is a type of immuno-oncology therapy, meaning that it acts on both cancer cells and the immune system. It is considered a radiation sensitizer since it blocks ENOX2, an enzyme involved in cancer cell survival. Blocking that enzyme makes these cells more vulnerable to the effects of chemotherapy and radiotherapy. Veyonda also was shown to activate the innate immune system, the body’s first line of defense, which increases its anti-cancer effects by promoting the elimination of cancer cells that might have survived chemotherapy and radiotherapy. In addition, preclinical studies showed that Veyonda induces an “abscopal response,” a poorly understood process in which local radiation directed at one tumor site also induces tumor shrinkage in distant, non-irradiated, metastatic lesions. The pivotal open-label, Phase 1b clinical trial, called DARRT-1 (NCT03307629), evaluated the safety and effectiveness of escalating doses of Veyonda in combination with low-dose radiotherapy. The study had enrolled 25 men with late-stage, progressive, mCRPC. I
Subscribe or to access all post and page content.